Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)

Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis





Conflict of Interest

- Dr. Rogawski serves as a paid consultant for Aquestive Therapeutics.
- Dr. Rogawski is currently or has previously served as consultant to other companies developing technology for similar applications, including Upsher-Smith Laboratories and Epalex Corporation.

How Does PharmFilm Work'

- Polymers are used as film formers to hold API and excipients in place
- Patented techniques are used to ensure the API is uniformly distributed throughout the film
- pH modifiers and permeation enhancers cause transport across the buccal mucosa
- Begins to dissolve immediately on application to mucosa
- API released from buccal film is absorbed by the transmucosal route and is also swallowed






Clobazam Oral Soluble Film (COSF)

- An new alternative clobazam dosage form for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older (outside the United States for anxiety disorders and epilepsy)
- May be easier for some caregivers to administer than oral tablets or oral liquid suspension
- Demonstrates capability of film technology

Bioequivalence Study of COSF (162018)

- Open-label, randomized, single-dose, 4-period, 4-arm, crossover, comparative bioavailability study
- Healthy, nonsmoking male and female volunteers (N=51)
- Treatments
 - COSF 10 mg (N=47)
 - COSF 20 mg (N=45)
 - Onfi[®] (clobazam) Tablet 10 mg (N=47)
 - Onfi[®] (clobazam) Tablet 20 mg (N=47)
- Washout: 28 days between dosing
- Blood sampling time points:
 - 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 28, 36, 48, 72, 96, 144, 240, 360, and 504 hours postdose in each period
- Safety: vital signs, physical exam, clinical labs, adverse events

Mean Plasma Concentration Profiles: COSF vs Onfi® (Study 162018)



20 mg Bioequivalence (Study 162018)

Bioequivalence of Clobazam Oral Soluble Film 20 mg vs Onfi® Tablets 20 mg – PK Population (N=45)

	Least-Squares Geometric Means			90% Geometric CI ²	
Parameter	COSF 20 mg	Onfi 20 mg	Ratio of Geo Means ¹ (%)	Lower	Upper
AUC _{0-t} (ng·h/mL)	10531.45	10152.24	/103.74 \	101.32	106.21
AUC _{0-inf} (ng·h/mL)	10712.10	10344.68	103.55	101.16	106.00
C _{max} (ng/mL)	386.59	376.84	\\102.59 /	95.43	110.28

¹Calculated using least-squares means according to formula e^(Difference) X 100.

²90% geometric confidence interval using In-transformed data.

10 mg Bioequivalence (Study 162018)

Bioequivalence of Clobazam Oral Soluble Film 10 mg vs Onfi® Tablets 10 mg – PK Population (N=47)

	Least-Squares Geometric Means			90% Geometric CI (%) ²	
Parameter	COSF 10 mg	Onfi 10 mg	Ratio of Geo Means ¹ (%)	Lower	Upper
AUC _{0-t} (ng·h/mL)	4554.83	4583.30	99.38	96.81	102.02
AUC _{0-inf} (ng·h/mL)	4714.55	4759.87	99.05	96.72	101.43
C _{max} (ng/mL)	179.96	188.53	95.45	90.19	101.03

¹Calculated using least-squares means according to formula e^(Difference) X 100.

²90% geometric confidence interval using In-transformed data.


Conclusions for COSF Bioequivalence Study (Study 162018)

- COSF 20 mg is bioequivalent to Onfi® 20 mg
- COSF 10 mg is bioequivalent to Onfi[®] 10 mg
- T_{max} values for COSF were comparable to those for Onfi
- COSF is dose proportional over the 10-20 mg range
- COSF at doses of 10 and 20 mg was safe and well tolerated

Diazepam Buccal Soluble Film (DBSF)

 An alternative to Diastat® AcuDial™ (diazepam rectal gel) for the treatment of acute repetitive seizures (seizure clusters)

DBSF Received FDA Fast Track Designation




- Fast track designation with option for rolling submission
- Expected NDA filings via 505(b)(2) pathway in early 2018

Completed Development Step Ongoing Development Step Future Development Step

DBSF: No 'PK Non-Responders'

- Diastat in some subjects did not produced expected plasma concentrations of diazepam
- In studies to date, DBSF has exhibited consistent plasma diazepam concentrations – including those subjects who did not obtain expected diazepam levels with Diastat

DBSF Pivotal Pharmacokinetics vs Diastat® AcuDial™ Rectal Gel¹ – Individual Subject




¹Fasted conditions

Completed Human PK Studies with DBSF


- Bioavailability of DBSF 5 mg and Diastat® AcuDial™ 5 mg Rectal Gel (Study 1899)
- Bioavailability of DBSF 20 mg and Diastat® AcuDial™ 20 mg Rectal Gel (Study 1900)
- Dose Proportionality of DBSF 5, 10, 15 mg (Study 162013)
- Bioavailability of DBSF 15 mg vs Diastat® AcuDial™ 5, 12.5, and 20 mg Rectal Gel (Study 162921)

Geometric Mean Diazepam Plasma Concentrations (Linear Scale) (Study 162013)



Dose Proportionality (C_{max}) (Study 162013)

C_{max} by Nominal Dose of Diazepam (Linear Scale)




C_{max} values were dose proportional.

DBSF: Diazepam 5, 10, 15 mg Buccal Soluble Film.

Dose Proportionality (AUC_{0-t}) (Study 162013)





AUC_{0-t} values were dose proportional.

DBSF: Diazepam 5, 10, 15 mg Buccal Soluble Film.

Relative Bioavailability (Study 162021)


C_{max} by Nominal Dose of Diazepam (Linear Scale)

DBSF

C_{max} is known to be dose proportional

Diastat® AcuDial™

C_{max} values were less than dose proportional



DBSF: Diazepam 15 mg Buccal Soluble Film.

Diastat AcuDial: Diazepam 5 mg (1 mL of 10 mg/2 mL), 12.5 mg (2.5 mL of 20 mg/4 mL), and 20 mg (4 mL of 20 mg/4 mL) rectal gel.

Relative Bioavailability (Study 162021)


DBSF

DBSF is known to be dose proportional for AUC

Diastat[®] AcuDial™

Diastat is dose proportional for AUC





DBSF: Diazepam 15 mg Buccal Soluble Film.

Diastat AcuDial: Diazepam 5 mg (1 mL of 10 mg/2 mL), 12.5 mg (2.5 mL of 20 mg/4 mL), and 20 mg (4 mL of 20 mg/4 mL) rectal gel.

Proposed DBSF Dosing: Dose of DBSF in mg Equivalent to Dose of Diastat® AcuDial™ in mg

Diastat Dose (mg)	Protocol- Specified DBSF Dose ¹ (mg)	
5	5	
7.5	7.5	
10	7.5	
12.5	10	
15	12.5	
17.5	12.5	
20	12.5	

 $^{^{1}}$ Dose of DBSF expected to provide C_{max} equal to C_{max} for Diastat dose.

PK Features of DBSF vs Diastat® AcuDial™

- Dose-proportional kinetics
- Less intersubject variability
- No bioavailability failures

 $T_{max}(h)$

Dose	DBSF	Diastat®		
(mg)	DBSF	AcuDial™		
5	0.81	0.50		
10	0.999			
12.5		1		
15	1.9–1.27			
20		1.5		

DBSF Studies Ongoing

- Adult EMU Study
- Pediatric EMU Study
- Long-term Safety Study

The End